Zoetis Inc. $ZTS Shares Sold by Bowen Hanes & Co. Inc.

Bowen Hanes & Co. Inc. lowered its position in shares of Zoetis Inc. (NYSE:ZTS) by 5.1% in the 2nd quarter, HoldingsChannel reports. The institutional investor owned 28,826 shares of the company’s stock after selling 1,549 shares during the period. Bowen Hanes & Co. Inc.’s holdings in Zoetis were worth $4,495,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Vanguard Group Inc. lifted its holdings in Zoetis by 0.8% in the 2nd quarter. Vanguard Group Inc. now owns 41,886,987 shares of the company’s stock valued at $6,532,276,000 after acquiring an additional 330,823 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Zoetis by 0.9% in the 2nd quarter. Geode Capital Management LLC now owns 11,081,301 shares of the company’s stock worth $1,721,356,000 after purchasing an additional 95,294 shares in the last quarter. Polen Capital Management LLC raised its holdings in shares of Zoetis by 17.6% in the 1st quarter. Polen Capital Management LLC now owns 8,796,847 shares of the company’s stock worth $1,448,401,000 after purchasing an additional 1,313,653 shares in the last quarter. Northern Trust Corp lifted its stake in Zoetis by 1.2% during the first quarter. Northern Trust Corp now owns 6,504,902 shares of the company’s stock valued at $1,071,032,000 after purchasing an additional 78,508 shares during the last quarter. Finally, Goldman Sachs Group Inc. boosted its holdings in Zoetis by 2.2% during the first quarter. Goldman Sachs Group Inc. now owns 5,146,024 shares of the company’s stock worth $847,293,000 after buying an additional 109,791 shares in the last quarter. 92.80% of the stock is currently owned by institutional investors.

Zoetis Price Performance

ZTS opened at $122.06 on Friday. The firm has a market capitalization of $53.79 billion, a P/E ratio of 21.01, a PEG ratio of 2.31 and a beta of 0.90. The stock has a fifty day moving average of $137.75 and a 200-day moving average of $150.17. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 1.05. Zoetis Inc. has a 12-month low of $115.25 and a 12-month high of $181.85.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Tuesday, November 4th. The company reported $1.70 earnings per share for the quarter, beating analysts’ consensus estimates of $1.62 by $0.08. The business had revenue of $2.40 billion for the quarter, compared to the consensus estimate of $2.42 billion. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.Zoetis’s revenue for the quarter was up .5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.58 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Equities analysts forecast that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 2nd. Stockholders of record on Friday, October 31st will be issued a $0.50 dividend. The ex-dividend date is Friday, October 31st. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.6%. Zoetis’s dividend payout ratio is currently 33.67%.

Wall Street Analyst Weigh In

ZTS has been the topic of several recent research reports. UBS Group decreased their price target on shares of Zoetis from $158.00 to $141.00 and set a “neutral” rating on the stock in a research report on Wednesday, November 5th. KeyCorp started coverage on Zoetis in a research note on Thursday. They set a “sector weight” rating for the company. JPMorgan Chase & Co. cut their target price on Zoetis from $230.00 to $200.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 5th. Stifel Nicolaus reduced their target price on Zoetis from $140.00 to $130.00 and set a “hold” rating for the company in a report on Tuesday. Finally, Piper Sandler lifted their price target on Zoetis from $210.00 to $215.00 and gave the stock an “overweight” rating in a research note on Monday, August 11th. Six analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $178.89.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.